GFM
PBYI icon

GF Fund Management’s Puma Biotechnology PBYI Stock Holding History

GF Fund Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.17K Buy
1,122
+133
+13% +$858 ﹤0.01% 586
2025
Q4 		$5.88K Buy
+989
New +$5.25K ﹤0.01% 616

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

GF Fund Management's PBYI Position: Q1 2026 in Review

GF Fund Management increased its Puma Biotechnology (PBYI) stake by 13% in Q1 2026, buying an estimated $858 and bringing the position to 1,122 shares worth $7.17K. The position accounts for ﹤0.01% of the portfolio, ranked #586.

GF Fund Management first reported a position in PBYI in Q4 2025 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • GF Fund Management held 1,122 shares of Puma Biotechnology worth $7.17K as of Q1 2026.
  • GF Fund Management bought 133 Puma Biotechnology shares in Q1 2026, an estimated $858.
  • Puma Biotechnology made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #586 holding.
  • GF Fund Management first reported a position in Puma Biotechnology in Q4 2025 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.